<DOC>
	<DOCNO>NCT00630331</DOCNO>
	<brief_summary>The present study evaluate clinical efficacy , safety , tolerability immunogenicity Novartis Vaccines ' cell-derived influenza vaccine egg-derived influenza vaccine healthy adult 18 49 year age .</brief_summary>
	<brief_title>Efficacy Study Two Influenza Vaccines Placebo Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1. subject 18 49 year age ; 2. good health determine medical history physical examination ; 3. able willing provide write informed consent prior study procedure ; 4. able comply study procedure , include availability willingness actively follow throughout ensue influenza season weekly telephone call comply need prompt collection nasal throat specimens event influenza symptom . 1. history anaphylaxis serious reaction administration vaccine , hypersensitivity egg , egg protein , chicken feather , influenza viral protein , neomycin , kanamycin , vaccine component , chemically related substance , component potential packaging material ; 2. health condition inactivate vaccine recommend Advisory Committee Immunization Practices ( ACIP ) include chronic disease pulmonary cardiovascular system ( include asthma ) , chronic metabolic disease ( include diabetes ) , renal dysfunction , hemoglobinopathy , immune deficiency disease ( include HIV infection ) ongoing immunosuppressive therapy ; 3. employment profession prone influenza transmission highrisk population ( exclusion specifically include nurse , physician , healthcare worker direct patient contact ; police , fire , rescue personnel ) ; live household immunocompromised person ; 4. history GuillainBarré syndrome ; 5. bleeding diathesis ; 6. receipt another investigational agent within 90 day prior enrollment study completion safety followup period another study , whichever longer , unwilling refuse participation another clinical study end study ; 7. receipt another vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior Visit 1 ; 8. laboratoryconfirmed influenza disease within 6 month prior Visit 1 ; 9. receipt influenza vaccine within 6 month prior Visit 1 plan receive influenza vaccine outside study ; 10. experienced temperature ( ≥100.0°F / ≥37.8°C ) and/or acute illness within 3 day prior study vaccination ; 11. pregnant breastfeed female ; 12. female childbearing potential sexually active , used birth control method detail section entitle `` Females Childbearing Potential '' least 2 month prior study entry ; 13. female childbearing potential sexually active , refusal use reliable contraceptive method detailed section entitle `` Females Childbearing Potential '' first 3 week vaccination ; 14. research staff directly involve clinical study family member household member research staff . Research staff individual direct indirect contact study subject , study site personnel access study document contain subject information . This would include receptionist , person schedule appointment make screen call , regulatory specialist , laboratory technician , etc . ; 15. condition , opinion investigator , might interfere evaluation study objective safety study subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Flu</keyword>
	<keyword>Cell Culture-Derived</keyword>
	<keyword>Egg-Derived</keyword>
	<keyword>Healthy Adults</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Trivalent</keyword>
	<keyword>Inactivated</keyword>
	<keyword>Influenza-Like Illness</keyword>
	<keyword>Vaccination</keyword>
</DOC>